Table 3.
Baseline Characteristics of Statin Initiators and Non-Initiators with Abnormal Baseline ALT Value After Propensity Score Matching
| Optum | MarketScan | |||
|---|---|---|---|---|
| Statin Initiators (n=82,451) | Non-Initiators (n=287,655) | Statin Initiators (n=66,959) | Non-Initiators (n=229,545) | |
| Age on index date (mean, SD) | 54.07 (11.13) | 53.94 (11.37) | 52.83 (9.53) | 52.58 (9.26) |
| Females (n, %) | 24,911 (30.2%) | 90,275 (31.4%) | 20,403 (30.5%) | 72,070 (31.4%) |
| Region | ||||
| Region - Northeast | 6,627 (8.0%) | 24,156 (8.4%) | 12,722 (19.0%) | 45,290 (19.7%) |
| Region - Midwest | 8,354 (10.1%) | 28,347 (9.9%) | 7,857 (11.7%) | 26,111 (11.4%) |
| Region - South | 49,793 (60.4%) | 173,339 (60.3%) | 39,565 (59.1%) | 134,890 (58.8%) |
| Region - West | 17,449 (21.2%) | 61,020 (21.2%) | 6,794 (10.1%) | 23,193 (10.1%) |
| Region - Other | 228 (0.3%) | 793 (0.3%) | 21 (0.0%) | 61 (0.0%) |
| Medications | ||||
| Medications associated with drug-induced liver injury (n,%) | 23,397 (28.4%) | 78,326 (27.2%) | 18,684 (27.9%) | 58,341 (25.4%) |
| Antidiabetic medication - Oral (n, %) | 18,863 (22.9%) | 65,239 (22.7%) | 15,700 (23.4%) | 52,877 (23.0%) |
| Antidiabetic medication - Insulin (n, %) | 3,891 (4.7%) | 12,290 (4.3%) | 3,190 (4.8%) | 9,240 (4.0%) |
| Antidiabetic medication - GLP-1 (n, %) | 1,249 (1.5%) | 4,123 (1.4%) | 1,183 (1.8%) | 3,805 (1.7%) |
| Non-statin antihyperlipidemic medications (n, %) | 6,069 (7.4%) | 21,854 (7.6%) | 4,866 (7.3%) | 16,513 (7.2%) |
| Pharmacy-dispensed acetaminophen (n, %) | 13,633 (16.5%) | 46,566 (16.2%) | 10,614 (15.9%) | 33,108 (14.4%) |
| Comorbidity | ||||
| BMI >30 or obesity surgery (n, %) | 12,084 (14.7%) | 42,627 (14.8%) | 7,258 (10.8%) | 25,065 (10.9%) |
| Smoking history (n, %) | 6,001 (7.3%) | 19,428 (6.8%) | 3,352 (5.0%) | 10,635 (4.6%) |
| Alcohol consumption (n, %) | 988 (1.2%) | 3,405 (1.2%) | 591 (0.9%) | 1,959 (0.9%) |
| Hypertension diagnosis (n, %) | 50,540 (61.3%) | 174,563 (60.7%) | 38,193 (57.0%) | 128,545 (56.0%) |
| Hyperlipidemia diagnosis (n, %) | 62,684 (76.0%) | 218,717 (76.0%) | 44,597 (66.6%) | 153,049 (66.7%) |
| Diabetes (Type 1 or Type 2) diagnosis (n, %) | 21,570 (26.2%) | 75,107 (26.1%) | 16,426 (24.5%) | 55,725 (24.3%) |
| Cardiovascular hospitalization (n, %) | 3,690 (4.5%) | 11,839 (4.1%) | 646 (1.0%) | 1,154 (0.5%) |
| Charlson Comorbidity Index (CCI) (mean, SD) | 0.69 (1.10) | 0.68 (1.13) | 0.56 (0.93) | 0.54 (0.94) |
| Results of most recent laboratory tests in baseline period | ||||
| LDL>130 mg/dl (n, %) | 41,094 (49.8%) | 145,674 (50.6%) | 35,855 (53.5%) | 122,776 (53.5%) |
| HDL<40 mg/dl (n, %) | 25,216 (30.6%) | 87,500 (30.4%) | 20,094 (30.0%) | 68,608 (29.9%) |
| Triglycerides >150 mg/dl (n, %) | 45,759 (55.5%) | 155,406 (54.0%) | 38,564 (57.6%) | 128,954 (56.2%) |
| Year of Index date | ||||
| 2007 | 3,944 (4.8%) | 13,752 (4.8%) | 626 (0.9%) | 2,162 (0.9%) |
| 2008 | 6,963 (8.4%) | 24,336 (8.5%) | 4,198 (6.3%) | 14,427 (6.3%) |
| 2009 | 8,240 (10.0%) | 28,858 (10.0%) | 3,844 (5.7%) | 13,150 (5.7%) |
| 2010 | 7,140 (8.7%) | 25,009 (8.7%) | 3,495 (5.2%) | 12,013 (5.2%) |
| 2011 | 6,040 (7.3%) | 21,064 (7.3%) | 10,204 (15.2%) | 35,091 (15.3%) |
| 2012 | 5,848 (7.1%) | 20,406 (7.1%) | 9,645 (14.4%) | 32,867 (14.3%) |
| 2013 | 7,834 (9.5%) | 27,376 (9.5%) | 9,515 (14.2%) | 32,589 (14.2%) |
| 2014 | 7,279 (8.8%) | 25,233 (8.8%) | 8,985 (13.4%) | 30,680 (13.4%) |
| 2015 | 8,241 (10.0%) | 28,707 (10.0%) | 8,608 (12.9%) | 29,603 (12.9%) |
| 2016 | 10,185 (12.4%) | 35,527 (12.4%) | 7,839 (11.7%) | 26,963 (11.7%) |
| 2017 | 10,737 (13.0%) | 37,387 (13.0%) | – | – |
Note: Baseline characteristics before matching are provided in the Appendix D.
Abbreviations: SD, standard deviation; BMI, body mass index.